Mustafa Aydin
Research Subjects
Mustafa Aydin has a total of 72 co-authors. Here are the top co-authors by number of shared publications:
- Mustafa Kemal Atilla
Department of Urology, Faculty of Medicine, Samsun University, 55080 Samsun, Türkiye
11 shared publications - Lokman Irkilata
Department of Urology, Samsun Training and Research Hospital, Samsun, Turkey
10 shared publications - Alper Bitkin
Department of Urology Bakırköy Dr. Sadi Konuk Training and Research Hospital University of Health Sciences Istanbul Türkiye
7 shared publications - Ebubekir Akgunes
UNIVERSITY OF HEALTH SCIENCES, SAMSUN HEALTH RESEARCH CENTER, DEPARTMENT OF SURGICAL MEDICAL SCIENCES, THE DEPARTMENT OF UROLOGY
5 shared publications - Emrah Küçük
Department of Urology, Faculty of Medicine, Samsun University, Samsun, Türkiye
4 shared publications - Mevlüt Keleş
Department of Urology, Faculty of Medicine, Ordu University, Ordu, Türkiye
4 shared publications
Latest Publications
- 18 March 2025
- Published by Springer Nature in World Journal of Urology
- Vol. 43 (1) , 1-8
Evaluation of ureteral injury using the PULS grading system in patients undergoing semi-rigid and flexible ureteroscopy
Purpose Ureteroscopy is one of the main diagnostic and treatment approaches for the upper urinary system luminal pathologies today. In recent years complication rates have decreased significantly. Standardizing ureteral damage after ureteroscopic interventions is of great importance for the management of complications. This study aimed to prospectively evaluate ureteral damage and factors affecting it in patients who underwent retrograde intrarenal surgery (RIRS) with ureteral access sheath (UAS), RIRS without UAS, and stone treatment with semi-rigid ureteroscope. Methods In this study, we included patients who underwent endoscopic surgery for ureter or kidney stones in our clinic. The ureteral pathologies of 202 patients who underwent RIRS with UAS, RIRS without the use of UAS, and semi-rigid ureteroscopy were prospectively evaluated using the Post-Ureteroscopic Lesion Scale (PULS). Results 75.7% of the lesions were PULS grade 1, 15.3% were grade 2. Lesions were most commonly located in the lower ureter during semi-rigid ureteroscopy, in the middle ureter during RIRS without a sheath, and in the upper ureter during RIRS with a sheath (p = 0.003). PULS 1 lesions (55.6%) were more commonly observed in the lower ureter, and PULS 2 lesions (41.9%) were also predominantly located in the lower ureter compared to other parts of the ureter. Conclusion It should be kept in mind that ureteral damage may occur after the ureteroscopy procedure. The degree and localization of the ureteral lesion may vary depending on the procedure to be chosen. Evaluating ureteral damage using the PULS scoring system is important for patient management.
- 18 March 2025
- Published by Springer Nature in World Journal of Urology
- Vol. 43 (1) , 1-8
Evaluation of ureteral injury using the PULS grading system in patients undergoing semi-rigid and flexible ureteroscopy
Purpose Ureteroscopy is one of the main diagnostic and treatment approaches for the upper urinary system luminal pathologies today. In recent years complication rates have decreased significantly. Standardizing ureteral damage after ureteroscopic interventions is of great importance for the management of complications. This study aimed to prospectively evaluate ureteral damage and factors affecting it in patients who underwent retrograde intrarenal surgery (RIRS) with ureteral access sheath (UAS), RIRS without UAS, and stone treatment with semi-rigid ureteroscope. Methods In this study, we included patients who underwent endoscopic surgery for ureter or kidney stones in our clinic. The ureteral pathologies of 202 patients who underwent RIRS with UAS, RIRS without the use of UAS, and semi-rigid ureteroscopy were prospectively evaluated using the Post-Ureteroscopic Lesion Scale (PULS). Results 75.7% of the lesions were PULS grade 1, 15.3% were grade 2. Lesions were most commonly located in the lower ureter during semi-rigid ureteroscopy, in the middle ureter during RIRS without a sheath, and in the upper ureter during RIRS with a sheath (p = 0.003). PULS 1 lesions (55.6%) were more commonly observed in the lower ureter, and PULS 2 lesions (41.9%) were also predominantly located in the lower ureter compared to other parts of the ureter. Conclusion It should be kept in mind that ureteral damage may occur after the ureteroscopy procedure. The degree and localization of the ureteral lesion may vary depending on the procedure to be chosen. Evaluating ureteral damage using the PULS scoring system is important for patient management.
- Open Access
- 1 January 2024
- Published by Endouroloji Dernegi in Endouroloji Bulteni
- Vol. 16 (3) , 99-107
Can the Neutrophil/Lymphocyte Ratio and Platelet/Lymphocyte Ratio Be Used to Predict the Risk of Ureteral Stricture Following Ureteroscopy?
Objective: The purpose of this study was to investigate whether the neutrophil/lymphocyte ratio (NLR) and platelet/lymphocyte ratio (PLR) can be used to predict the development of ureteral stricture or difficult ureter in patients who had previously undergone endoscopic upper urinary tract surgery. Material and Methods: This observational study was performed between April 2022 and April 2023 at the Samsun Training and Research Hospital Urology Department, Türkiye. One hundred thirty patients who had undergone prior endoscopic upper urinary tract surgery were included. These were divided into two groups, with (Group 1) and without (Group 2) ureteral stricture. The diagnosis of ureteral stricture was based on direct endoscopy or retrograde pyelography. The groups’ sociodemographic characteristics, clinical data, and NLR and PLR values were then compared. Results: The patients’ mean ages were 49.89±14.40 years in Group 1 and 48.92±14.60 in Group 2 (p = 0.704). No statistically significant differences were observed between the groups in terms of sex, body mass index, or comorbidity. However, significant differences were determined in terms of passage of kidney stones and numbers of surgical procedures performed (p = 0.001 and p
- 1 January 2024
- Published by Endouroloji Dernegi in Endouroloji Bulteni
- Vol. 16 (3) , 99-107
Open AccessCan the Neutrophil/Lymphocyte Ratio and Platelet/Lymphocyte Ratio Be Used to Predict the Risk of Ureteral Stricture Following Ureteroscopy?
Objective: The purpose of this study was to investigate whether the neutrophil/lymphocyte ratio (NLR) and platelet/lymphocyte ratio (PLR) can be used to predict the development of ureteral stricture or difficult ureter in patients who had previously undergone endoscopic upper urinary tract surgery. Material and Methods: This observational study was performed between April 2022 and April 2023 at the Samsun Training and Research Hospital Urology Department, Türkiye. One hundred thirty patients who had undergone prior endoscopic upper urinary tract surgery were included. These were divided into two groups, with (Group 1) and without (Group 2) ureteral stricture. The diagnosis of ureteral stricture was based on direct endoscopy or retrograde pyelography. The groups’ sociodemographic characteristics, clinical data, and NLR and PLR values were then compared. Results: The patients’ mean ages were 49.89±14.40 years in Group 1 and 48.92±14.60 in Group 2 (p = 0.704). No statistically significant differences were observed between the groups in terms of sex, body mass index, or comorbidity. However, significant differences were determined in terms of passage of kidney stones and numbers of surgical procedures performed (p = 0.001 and p
- Open Access
- 1 March 2023
- Published by Galenos Yayinevi in Üroonkoloji Bülteni
- Vol. 22 (1) , 15-19
Preoperative De Ritis Ratio for the Evaluation of Recurrence and Progression in Non-muscle Invasive Bladder Cancer
- 1 March 2023
- Published by Galenos Yayinevi in Üroonkoloji Bülteni
- Vol. 22 (1) , 15-19
Open AccessPreoperative De Ritis Ratio for the Evaluation of Recurrence and Progression in Non-muscle Invasive Bladder Cancer
- Open Access
- 30 November 2022
- Published by Ordu University in MIDDLE BLACK SEA JOURNAL OF HEALTH SCIENCE
- Vol. 8 (4) , 515-524
Does transrectal prostate biopsy cause sexual dysfunction? Cross-sectional evaluation of 252 patients
Objective: In this study, we aimed to evaluate whether there are negative effects of transrectal prostate biopsy (TPB) on sexual functions (SF).Methods: This study includes 252 male patients evaluated prospectively who underwent TPB in our clin-ic between January 2015 and September 2016. Patients with chronic diseases (e.g. diabetes mellitus, hy-pertension) and the use of drugs (e.g. antihypertensive drugs, antidepressants) that can affect SF were excluded. Patients completed the IIEF-15 forms before TPB, in the first, third, and sixth months after TPB. Patients were evaluated in terms of erectile function (EF), orgasmic functions (OF), sexual desire (SD), intercourse satisfaction (IS), and overall sexual satisfaction (OSS).Results: The relationship between follow-up time and EF, OF, SD, IS and OSS scores were analyzed. A significant difference was observed in EF scores before TPB and in the first month after TPB (p=0,007). However, in subgroup analyses, it was determined that this significant difference was only in the PCa patients. In BPH-diagnosed patients, there was no significant difference between the ED score and the follow-up times. OF, IS, and OOS scores in the 1st, 3rd, and 6th months decreased significantly according to the initial score (p = 0,001). SD scores showed no significant differences among follow-ups (p=0,191).Conclusion: Erectile dysfunction (ED) is not likely for all patients who undergo TPB. Our study revealed that PCa patients are short-term sufferers of ED after TPB. But, according to our data, it is not clear whether the cause is TPB or anxiety due to PCa diagnosis.
- 30 November 2022
- Published by Ordu University in MIDDLE BLACK SEA JOURNAL OF HEALTH SCIENCE
- Vol. 8 (4) , 515-524
Open AccessDoes transrectal prostate biopsy cause sexual dysfunction? Cross-sectional evaluation of 252 patients
Objective: In this study, we aimed to evaluate whether there are negative effects of transrectal prostate biopsy (TPB) on sexual functions (SF).Methods: This study includes 252 male patients evaluated prospectively who underwent TPB in our clin-ic between January 2015 and September 2016. Patients with chronic diseases (e.g. diabetes mellitus, hy-pertension) and the use of drugs (e.g. antihypertensive drugs, antidepressants) that can affect SF were excluded. Patients completed the IIEF-15 forms before TPB, in the first, third, and sixth months after TPB. Patients were evaluated in terms of erectile function (EF), orgasmic functions (OF), sexual desire (SD), intercourse satisfaction (IS), and overall sexual satisfaction (OSS).Results: The relationship between follow-up time and EF, OF, SD, IS and OSS scores were analyzed. A significant difference was observed in EF scores before TPB and in the first month after TPB (p=0,007). However, in subgroup analyses, it was determined that this significant difference was only in the PCa patients. In BPH-diagnosed patients, there was no significant difference between the ED score and the follow-up times. OF, IS, and OOS scores in the 1st, 3rd, and 6th months decreased significantly according to the initial score (p = 0,001). SD scores showed no significant differences among follow-ups (p=0,191).Conclusion: Erectile dysfunction (ED) is not likely for all patients who undergo TPB. Our study revealed that PCa patients are short-term sufferers of ED after TPB. But, according to our data, it is not clear whether the cause is TPB or anxiety due to PCa diagnosis.
- 1 June 2022
- Published by Galenos Yayinevi in Üroonkoloji Bülteni
- Vol. 21 (2) , 52-57
The Evaluation of Goal-Directed Antibiotics Prophylaxis Applied Via Rectal Swab Before Transrectal Ultrasound-Guided Prostate Biopsy
- 1 June 2022
- Published by Galenos Yayinevi in Üroonkoloji Bülteni
- Vol. 21 (2) , 52-57
The Evaluation of Goal-Directed Antibiotics Prophylaxis Applied Via Rectal Swab Before Transrectal Ultrasound-Guided Prostate Biopsy
- Open Access
- 31 May 2022
- Published by Endouroloji Dernegi in Endouroloji Bulteni
- Vol. 14 (2) , 42-48
Retrograde intrarenal cerrahide taşsızlık oranlarını etkileyen faktörler
Amaç: Böbrek taşı nedeniyle retrograt intrarenal cerrahi uygulanan olgularda taşsızlık elde etmede etkili olan faktörleri saptamayı amaçladık. Gereç ve Yöntemler: Ocak 2021- Temmuz 2021 tarihleri arasında kliniğimizde retrograt intrarenal cerrahi (RİRC) uygulanan 160 olgunun verilerini retrospektif olarak analiz ettik. Hastaların demografik özellikleri, bilgisayarlı tomografi (BT) görüntüleri üzerinden ölçümü yapılan taş ve böbrek kalisiyel anatomisi ile ilgili parametreleri, üreter erişim kılıfı (ÜEK) kullanılma durumu ve cerrahi süre analiz edildi. Postoperatif 1.ayda direkt üriner sistem grafisi (DÜSG) veya BT görüntülerindeki rezidü taşın 2 mm’den küçük olması veya hiç taş olmaması cerrahi için başarılı kabul edildi. Hastalar taşssızlık durumuna göre taşsız (Grup1) ve rezidü taşa sahip (Grup 2) olmak üzere iki gruba ayrıldı. Ayrıca böbrekteki taş lokalizasyona göre alt pol olan (45 derece ve üstü ile altı) ve olmayan diye alt grublara ayrıldı. Gruplar operasyon sonrası rezidü varlığına göre kıyaslandı. Bulgular: Grup 1 ve Grup 2 için cinsiyetin dağılımları, vücut kitle indeksi (VKİ), taraf, ÜEK kullanımı, opasite durumu, infindibulopelvik açı (İPA) ve infundibuler uzunluk için fark yoktu (p>0,05). Taşssız olan Grup 1’de infundibuler genişlik daha fazla idi (p>0,021). Birden fazla taşı olanlarda rezidü, tek taşı olanlara göre fazla idi (p>0,048). Taş hacmi ve taş dansitesi için taşsızlık üzerine etkileyici sonuç bulmadık. Böbrekteki lokalizasyona göre alt pol olanlarda rezidü fazlaydı (p>0,001). Ancak alt pol taşları olanlarda 45 derece üstü ve altı olanlar arasında fark yoktu (p>0,050). Sonuç: Retrograd intrarenal taş cerrahisi tedavisinde, birden fazla taşın olması, alt pol taşın olması, infundibüler genişliğin az olması taşsızlığı olumsuz etkileyen faktörler olarak öngörülebilir.
- 31 May 2022
- Published by Endouroloji Dernegi in Endouroloji Bulteni
- Vol. 14 (2) , 42-48
Open AccessRetrograde intrarenal cerrahide taşsızlık oranlarını etkileyen faktörler
Amaç: Böbrek taşı nedeniyle retrograt intrarenal cerrahi uygulanan olgularda taşsızlık elde etmede etkili olan faktörleri saptamayı amaçladık. Gereç ve Yöntemler: Ocak 2021- Temmuz 2021 tarihleri arasında kliniğimizde retrograt intrarenal cerrahi (RİRC) uygulanan 160 olgunun verilerini retrospektif olarak analiz ettik. Hastaların demografik özellikleri, bilgisayarlı tomografi (BT) görüntüleri üzerinden ölçümü yapılan taş ve böbrek kalisiyel anatomisi ile ilgili parametreleri, üreter erişim kılıfı (ÜEK) kullanılma durumu ve cerrahi süre analiz edildi. Postoperatif 1.ayda direkt üriner sistem grafisi (DÜSG) veya BT görüntülerindeki rezidü taşın 2 mm’den küçük olması veya hiç taş olmaması cerrahi için başarılı kabul edildi. Hastalar taşssızlık durumuna göre taşsız (Grup1) ve rezidü taşa sahip (Grup 2) olmak üzere iki gruba ayrıldı. Ayrıca böbrekteki taş lokalizasyona göre alt pol olan (45 derece ve üstü ile altı) ve olmayan diye alt grublara ayrıldı. Gruplar operasyon sonrası rezidü varlığına göre kıyaslandı. Bulgular: Grup 1 ve Grup 2 için cinsiyetin dağılımları, vücut kitle indeksi (VKİ), taraf, ÜEK kullanımı, opasite durumu, infindibulopelvik açı (İPA) ve infundibuler uzunluk için fark yoktu (p>0,05). Taşssız olan Grup 1’de infundibuler genişlik daha fazla idi (p>0,021). Birden fazla taşı olanlarda rezidü, tek taşı olanlara göre fazla idi (p>0,048). Taş hacmi ve taş dansitesi için taşsızlık üzerine etkileyici sonuç bulmadık. Böbrekteki lokalizasyona göre alt pol olanlarda rezidü fazlaydı (p>0,001). Ancak alt pol taşları olanlarda 45 derece üstü ve altı olanlar arasında fark yoktu (p>0,050). Sonuç: Retrograd intrarenal taş cerrahisi tedavisinde, birden fazla taşın olması, alt pol taşın olması, infundibüler genişliğin az olması taşsızlığı olumsuz etkileyen faktörler olarak öngörülebilir.
- 14 May 2020
- Published by Wiley in LUTS: Lower Urinary Tract Symptoms
- Vol. 13 (1) , 17-21
Does tamsulosin or mirabegron improve ureteral stent‐related symptoms? A prospective placebo‐controlled study
Objective: The main objective of this study was to evaluate the efficacy of tamsulosin or mirabegron on ureteral stent‐related symptoms.Patients and methods: This was a prospective, randomized, controlled, and single‐blinded study. In total, 180 patients who had undergone ureterolithotripsy and ureteral stent insertion were included. Patients were randomly divided into three groups as follows: Group 1 was the control group taking placebo; group 2 was administered tamsulosin (0.4 mg) once a day; and group 3 received mirabegron (50 mg) once a day. The Turkish version of the ureteral stent symptom questionnaire was filled out after 4 weeks.Results: After excluding patients who were lost to follow‐up, 161 patients were included in the final analysis. Analgesic usage doses were lower in the tamsulosin (5.1 ± 1.8) and mirabegron (4.5 ± 1.4) groups than in the control group (5.9 ± 2.1; P < .001). The urinary symptoms score was lower in tamsulosin group than it was in the control group (22.1 vs 27.8; P = .001); however, the other scores (body pain, general health, work performance, sexual matters, and other problems) were similar between the groups.Conclusions: Tamsulosin improves only urinary symptoms due to the ureteral stent and decreases the need for analgesics. Mirabegron has no effect on ureteral stent‐related symptoms, but it decreases analgesic need.
- 14 May 2020
- Published by Wiley in LUTS: Lower Urinary Tract Symptoms
- Vol. 13 (1) , 17-21
Does tamsulosin or mirabegron improve ureteral stent‐related symptoms? A prospective placebo‐controlled study
Objective: The main objective of this study was to evaluate the efficacy of tamsulosin or mirabegron on ureteral stent‐related symptoms.Patients and methods: This was a prospective, randomized, controlled, and single‐blinded study. In total, 180 patients who had undergone ureterolithotripsy and ureteral stent insertion were included. Patients were randomly divided into three groups as follows: Group 1 was the control group taking placebo; group 2 was administered tamsulosin (0.4 mg) once a day; and group 3 received mirabegron (50 mg) once a day. The Turkish version of the ureteral stent symptom questionnaire was filled out after 4 weeks.Results: After excluding patients who were lost to follow‐up, 161 patients were included in the final analysis. Analgesic usage doses were lower in the tamsulosin (5.1 ± 1.8) and mirabegron (4.5 ± 1.4) groups than in the control group (5.9 ± 2.1; P < .001). The urinary symptoms score was lower in tamsulosin group than it was in the control group (22.1 vs 27.8; P = .001); however, the other scores (body pain, general health, work performance, sexual matters, and other problems) were similar between the groups.Conclusions: Tamsulosin improves only urinary symptoms due to the ureteral stent and decreases the need for analgesics. Mirabegron has no effect on ureteral stent‐related symptoms, but it decreases analgesic need.
- 23 December 2019
- Published by Springer Nature in International Urology and Nephrology
- Vol. 52 (5) , 835-840
Efficacy of silodosin or mirabegron in medical expulsive therapy for ureteral stones: a prospective, randomized-controlled study
Objective To evaluate the efficacy of silodosin or mirabegron as a medical expulsive therapy for ureteric stones in adults. Patients-method This is a prospective, randomized multicentric study. Patients who had ureter stones in size between 4 and 10 mm were assessed prospectively. Patients were divided into three groups with equal randomization. Group 1 was the control group; group 2 took silodosin 8 mg, and group 3 took mirabegron 50 mg once daily. Results All 169 patients were included in the final analysis. The spontaneous expulsion rate was similar between groups. In patients with distal localization, the stone expulsion interval was shorter in the silodosin group (7.1 ± 4.5 days) than the control (12 ± 8.7) (p = 0.034). In patients with stone size smaller than 6 mm, the stone expulsion interval was shorter in the silodosin group (5.8 ± 4) than the control (12.2 ± 2.8) (p = 0.004); the analgesic requirement was less in the silodosin group (1.4 ± 1.3) than in the control (3.6 ± 2.8) (p = 0.028). Mirabegron had no effect on stone expulsion interval in any analysis. In patients with distal localization or stone size bigger or equal to 6 mm, the need for an analgesic was less in the mirabegron group (1.8 ± 1.9) (1.9 ± 1.8) than in the control (3.6 ± 2.3) (3.2 ± 1.8), respectively (p = 0.004) (p = 0.017). Conclusions Silodosin or mirabegron does not improve the stone expulsion rate. Silodosin improves the stone expulsion interval and decreases the need for an analgesic or < 6 mm stones. Mirabegron has no effect on the stone expulsion interval, but decreases the need for an analgesic in patients with distal or sized ≥ 6 mm stones.
- 23 December 2019
- Published by Springer Nature in International Urology and Nephrology
- Vol. 52 (5) , 835-840
Efficacy of silodosin or mirabegron in medical expulsive therapy for ureteral stones: a prospective, randomized-controlled study
Objective To evaluate the efficacy of silodosin or mirabegron as a medical expulsive therapy for ureteric stones in adults. Patients-method This is a prospective, randomized multicentric study. Patients who had ureter stones in size between 4 and 10 mm were assessed prospectively. Patients were divided into three groups with equal randomization. Group 1 was the control group; group 2 took silodosin 8 mg, and group 3 took mirabegron 50 mg once daily. Results All 169 patients were included in the final analysis. The spontaneous expulsion rate was similar between groups. In patients with distal localization, the stone expulsion interval was shorter in the silodosin group (7.1 ± 4.5 days) than the control (12 ± 8.7) (p = 0.034). In patients with stone size smaller than 6 mm, the stone expulsion interval was shorter in the silodosin group (5.8 ± 4) than the control (12.2 ± 2.8) (p = 0.004); the analgesic requirement was less in the silodosin group (1.4 ± 1.3) than in the control (3.6 ± 2.8) (p = 0.028). Mirabegron had no effect on stone expulsion interval in any analysis. In patients with distal localization or stone size bigger or equal to 6 mm, the need for an analgesic was less in the mirabegron group (1.8 ± 1.9) (1.9 ± 1.8) than in the control (3.6 ± 2.3) (3.2 ± 1.8), respectively (p = 0.004) (p = 0.017). Conclusions Silodosin or mirabegron does not improve the stone expulsion rate. Silodosin improves the stone expulsion interval and decreases the need for an analgesic or < 6 mm stones. Mirabegron has no effect on the stone expulsion interval, but decreases the need for an analgesic in patients with distal or sized ≥ 6 mm stones.
- 1 November 2019
- Published by Elsevier in Actas Urológicas Españolas
- Vol. 43 (9) , 503-508
Correlación entre el índice neutrófilo/linfocito y las puntuaciones de riesgo en el cáncer de vejiga no músculo-invasivo
- 1 November 2019
- Published by Elsevier in Actas Urológicas Españolas
- Vol. 43 (9) , 503-508
Correlación entre el índice neutrófilo/linfocito y las puntuaciones de riesgo en el cáncer de vejiga no músculo-invasivo
- Open Access
- 1 January 2019
- Published by The Scientific and Technological Research Council of Turkey (TUBITAK-ULAKBIM) - DIGITAL COMMONS JOURNALS in TURKISH JOURNAL OF MEDICAL SCIENCES
- Vol. 49 (6) , 1701-1706
DOES TRANSRECTAL ULTRASONOGRAPHY-GUIDED BIOPSY OF THE PROSTATE LEAD TO POSSIBLE FURTHER METASTASIS VIA CIRCULATING TUMOR CELLS?
Background/aim: We evaluate whether transrectal ultrasonography (rRUS)-guided prostate biopsy might lead to spillage of tumor cells into peripheral blood as a result of disruption of the epithelial barrier and ultimately result in metastasis. Materials and methods: Eighty-eight patients underwent 'FRUS-guided prostate needle biopsy due to prostate-specific antigen (PSA) increase or abnormal digital rectal examination at the Samsun Research and Training Hospital (Samsun, Turkey) between April 2016 and September 2018. Approximately 10 mL of whole blood was collected from patients before, 1 week after, and 1 month after biopsy. Samples were analyzed for CD117 positivity and prostate-specific membrane antigen (PSMA) levels using flow cytometry. Patients with pathologically determined prostate cancer and without CD117 positivity before biopsy were included in the study. The study group thus consisted of 55 patients. Results: Subjects' PSA levels ranged from 2.3 to 40.0 ng/mL (median: 7.9 ng/mL), and their Gleason score was a median of 7 (range: 5-9). PSMA levels ranged between 9.3 ng/mL and 118.5 ng/mL and CD117 antigen levels between 0 and 5. We detected no CD117-positive cells in blood samples collected 7 days or 1 month after biopsy. Conclusion: We detected no circulating tumor cells in the peripheral circulation following biopsy. Prostate needle biopsy seems to be a safe method in terms of spillage of tumor cells into blood circulation as a possible cause of further metastasis.
- 1 January 2019
- Published by The Scientific and Technological Research Council of Turkey (TUBITAK-ULAKBIM) - DIGITAL COMMONS JOURNALS in TURKISH JOURNAL OF MEDICAL SCIENCES
- Vol. 49 (6) , 1701-1706
Open AccessDOES TRANSRECTAL ULTRASONOGRAPHY-GUIDED BIOPSY OF THE PROSTATE LEAD TO POSSIBLE FURTHER METASTASIS VIA CIRCULATING TUMOR CELLS?
Background/aim: We evaluate whether transrectal ultrasonography (rRUS)-guided prostate biopsy might lead to spillage of tumor cells into peripheral blood as a result of disruption of the epithelial barrier and ultimately result in metastasis. Materials and methods: Eighty-eight patients underwent 'FRUS-guided prostate needle biopsy due to prostate-specific antigen (PSA) increase or abnormal digital rectal examination at the Samsun Research and Training Hospital (Samsun, Turkey) between April 2016 and September 2018. Approximately 10 mL of whole blood was collected from patients before, 1 week after, and 1 month after biopsy. Samples were analyzed for CD117 positivity and prostate-specific membrane antigen (PSMA) levels using flow cytometry. Patients with pathologically determined prostate cancer and without CD117 positivity before biopsy were included in the study. The study group thus consisted of 55 patients. Results: Subjects' PSA levels ranged from 2.3 to 40.0 ng/mL (median: 7.9 ng/mL), and their Gleason score was a median of 7 (range: 5-9). PSMA levels ranged between 9.3 ng/mL and 118.5 ng/mL and CD117 antigen levels between 0 and 5. We detected no CD117-positive cells in blood samples collected 7 days or 1 month after biopsy. Conclusion: We detected no circulating tumor cells in the peripheral circulation following biopsy. Prostate needle biopsy seems to be a safe method in terms of spillage of tumor cells into blood circulation as a possible cause of further metastasis.